Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation

Journal of Heart and Lung Transplantation

Volumn 34, Issue 8, 2015, Pages 1112-1119

  Delgado, Juan F ^a   Reyne, Ana García ^a   De Dios, Santiago ^a   López Medrano, Francisco ^a   Jurado, Alfonso ^a   Juan, Rafael San ^a   Ruiz Cano, María José ^a   Dolores Folgueira, M ^a   Gómez Sánchez, Miguel Ángel ^a   Aguado, José María ^a   Lumbreras, Carlos ^a  

^a Instituto de Investigación Hospital 12 de Octubre ^*  (Spain)

Author keywords

calcium channel blocker; cardiac allograft vasculopathy; cardiac angiography; cytomegalovirus infection; heart transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; OKT 3; PREDNISONE;

ACUTE GRAFT REJECTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PATIENT MONITORING; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK FACTOR; SYMPTOMATOLOGY; VIREMIA; ADVERSE EFFECTS; AGED; CYTOMEGALOVIRUS INFECTIONS; DISEASE FREE SURVIVAL; GRAFT REJECTION; HEART FAILURE; MORTALITY; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; AGED; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; FEMALE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84943581251     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2015.03.015     Document Type: Article

References (40)

1. J. Stehlik, L.B. Edwards, A.Y. Kucheryavaya, and et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report - 2012 J Heart Lung Transplant 31 2012 1052 1064
2. D. Schmauss, and M. Weis Cardiac allograft vasculopathy: recent developments Circulation 117 2008 2131 2141
3. M.R. Mehra, M.G. Crespo-Leiro, A. Dipchand, and et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010 J Heart Lung Transplant 29 2010 717 727
4. O. Prada-Delgado, R. Estevez-Loureiro, M.J. Paniagua-Martin, A. Lopez-Sainz, and M.G.P. Crespo-Leiro revalence and prognostic value of cardiac allograft vasculopathy 1 year after heart transplantation according to the ISHLT recommended nomenclature J Heart Lung Transplant 31 2012 332 333
5. M.J. Perez-Sola, J.J. Caston, R. Solana, A. Rivero, and J. Torre-Cisneros Indirect effects of cytomegalovirus infection in solid organ transplant recipients Enferm Infecc Microbiol Clin 26 2008 38 47
6. J.R. Braga, I.S. Santos, M. McDonald, P.S. Shah, and H.J. Ross Factors associated with the development of cardiac allograft vasculopathy - a systematic review of observational studies Clin Transplant 26 2012 E111 E124
7. J.P. Vandenbroucke, E. von Elm, D.G. Altman, and et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration Epidemiology 18 2007 805 835
8. C.N. Kotton, D. Kumar, A.M. Caliendo, and et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation Transplantation 89 2010 779 795
9. S. Husain, M.L. Mooney, L. Danziger-Isakov, and et al. A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients J Heart Lung Transplant 30 2011 361 374
10. S. Stewart, G.L. Winters, M.C. Fishbein, and et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection J Heart Lung Transplant 24 2005 1710 1720
11. J.A. Kobashigawa, J.M. Tobis, R.C. Starling, and et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years J Am Coll Cardiol 45 2005 1532 1537
12. M.G. Crespo-Leiro, R. Marzoa-Rivas, E. Barge-Caballero, and M.J. Paniagua-Martin Prevention and treatment of coronary artery vasculopathy Curr Opin Organ Transplant 17 2012 546 550
13. H.P. Brunner-La Rocca, J. Schneider, A. Kunzli, M. Turina, and W. Kiowski Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease Transplantation 65 1998 538 543
14. C. Courivaud, J. Bamoulid, J.M. Chalopin, and et al. Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients J Infect Dis 207 2013 1569 1575
15. H.A. Valantine The role of viruses in cardiac allograft vasculopathy Am J Transplant 4 2004 169 177
16. L. Potena, F. Grigioni, P. Ortolani, and et al. Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study Transplantation 75 2003 839 843
17. J.L. Melnick, B.L. Petrie, G.R. Dreesman, J. Burek, C.H. McCollum, and M.E. DeBakey Cytomegalovirus antigen within human arterial smooth muscle cells Lancet 2 1983 644 647
18. J.L. Melnick, C. Hu, J. Burek, E. Adam, and M.E. DeBakey Cytomegalovirus DNA in arterial walls of patients with atherosclerosis J Med Virol 42 1994 170 174
19. S.E. Epstein, J. Zhu, A.H. Najafi, and M.S. Burnett Insights into the role of infection in atherogenesis and in plaque rupture Circulation 119 2009 3133 3141
20. F.R. Stassen, X. Vega-Cordova, I. Vliegen, and C.A. Bruggeman Immune activation following cytomegalovirus infection: more important than direct viral effects in cardiovascular disease? J Clin Virol 35 2006 349 353
21. B. Reinhardt, T. Mertens, U. Mayr-Beyrle, and et al. HCMV infection of human vascular smooth muscle cells leads to enhanced expression of functionally intact PDGF beta-receptor Cardiovasc Res 67 2005 151 160
22. M.C. van Dam-Mieras, A.D. Muller, V.W. van Hinsbergh, W.J. Mullers, P.H. Bomans, and C.A. Bruggeman The procoagulant response of cytomegalovirus infected endothelial cells Thromb Haemost 68 1992 364 370
23. G. Pawelec, E. Derhovanessian, A. Larbi, J. Strindhall, and A. Wikby Cytomegalovirus and human immunosenescence Rev Med Virol 19 2009 47 56
24. T. Hussain, M. Burch, M.J. Fenton, and et al. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children Circulation 115 2007 1798 1805
25. K.B. Lemstrom, J.H. Bruning, C.A. Bruggeman, and et al. Cytomegalovirus infection-enhanced allograft arteriosclerosis is prevented by DHPG prophylaxis in the rat Circulation 90 1994 1969 1978
26. K. Lemstrom, P. Koskinen, L. Krogerus, M. Daemen, C. Bruggeman, and P. Hayry Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection Circulation 92 1995 2594 2604
27. K. Lemstrom, R. Sihvola, C. Bruggeman, P. Hayry, and P. Koskinen Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat Circulation 95 1997 2614 2616
28. H.A. Valantine, S.Z. Gao, S.G. Menon, and et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study Circulation 100 1999 61 66
29. H.A. Valantine, H. Luikart, R. Doyle, and et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone Transplantation 72 2001 1647 1652
30. L. Potena, C.T. Holweg, C. Chin, and et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection Transplantation 82 2006 398 405
31. J.J. Kelly, R.G. Walker, A.J. d'Apice, and P. Kincaid-Smith A prospective study of the effect of diltiazem in renal allograft recipients receiving cyclosporine A: preliminary results Transplant Proc 22 1990 2127 2128
32. J.S. Schroeder, S.Z. Gao, E.L. Alderman, and et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients N Engl J Med 328 1993 164 170
33. U. Kunzendorf, G. Walz, J. Brockmoeller, and et al. Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients Transplantation 52 1991 280 284
34. J.F. Delgado, V. Sanchez, C.S. de la Calzada, and et al. Impact of diltiazem administration and cyclosporine levels on the incidence of acute rejection in heart transplant patients Transpl Int 16 2003 676 680
35. S. Mies, P.C. Massarollo, E.R. Figueira, R.M. Leitao, and S. Raia Lower incidence of liver graft rejection in patients on diltiazem plus cyclosporine therapy Transplant Proc 30 1998 1437 1438
36. N. Lapointe, H. Chen, S. Qi, D. Xu, P. Daloze, and L. Dumont Immunomodulating effects of second-generation calcium channel blockers on experimental heart transplantation Eur Surg Res 31 1999 259 266
37. L. Dumont, H. Chen, P. Daloze, D. Xu, and D. Garceau Immunosuppressive properties of the benzothiazepine calcium antagonists diltiazem and clentiazem, with and without cyclosporine, in heterotopic rat heart transplantation Transplantation 56 1993 181 184
38. D. Libersan, R. Marchand, S. Montplaisir, C. Chartrand, and L. Dumont Cardioprotective effects of diltiazem during acute rejection on heterotopic heart transplants Eur Surg Res 29 1997 229 236
39. J.A. Kobashigawa, S. Katznelson, H. Laks, and et al. Effect of pravastatin on outcomes after cardiac transplantation N Engl J Med 333 1995 621 627
40. M.R. Mehra, H.O. Ventura, F.W. Smart, T.J. Collins, S.R. Ramee, and D.D. Stapleton An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy Am J Cardiol 75 1995 853 854